Effect of supplementation in treatment of polycystic ovary syndrome

Phase 3

• Conditions: Polycystic ovary syndrome.; Polycystic ovarian syndrome; E28.2

• Registration Number: IRCT201506105623N44
• Lead Sponsor: Kashan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 November 2019

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Women aged 18-40 years old diagnosed with PCOS

Exclusion Criteria

Individuals with elevated levels of prolactin
Thyroid disorder
Endocrine diseases including diabetes or impaired glucose tolerance
Gastrointestinal problems

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Free testosterone. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.

Secondary Outcome Measures

Name	Time	Method
Prolactin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;FSH. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;LH. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Total antioxidant. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;17-OH progesterone. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;DHEA. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.